Impact of a Cancer Gene Variant Reclassification Program Over a 20-Year Period.

Esterling, Lisa; Wijayatunge, Ranjula; Brown, Krystal; Morris, Brian; Hughes, Elisha; Pruss, Dmitry; Manley, Susan; Bowles, Karla R; Ross, Theodora S

Esterling, Lisa; Wijayatunge, Ranjula; Brown, Krystal; Morris, Brian; Hughes, Elisha; Pruss, Dmitry; Manley, Susan; Bowles, Karla R; Ross, Theodora S.

Afiliación

Esterling L; Myriad Genetic Laboratories, Salt Lake City, UT.
Wijayatunge R; University of Texas Southwestern Medical Center, Dallas, TX.
Brown K; Myriad Genetic Laboratories, Salt Lake City, UT.
Morris B; Myriad Genetic Laboratories, Salt Lake City, UT.
Hughes E; Myriad Genetic Laboratories, Salt Lake City, UT.
Pruss D; Myriad Genetic Laboratories, Salt Lake City, UT.
Manley S; Myriad Genetic Laboratories, Salt Lake City, UT.
Bowles KR; Myriad Genetic Laboratories, Salt Lake City, UT.
Ross TS; University of Texas Southwestern Medical Center, Dallas, TX.

JCO Precis Oncol ; 42020.

Article en En | MEDLINE | ID: mdl-32923914

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JCO Precis Oncol Año: 2020 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: JCO Precis Oncol Año: 2020 Tipo del documento: Article